Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Agios Pharmaceuticals's current 10-Year Share Buyback Ratio was -3.20%.
MEX:AGIO's 10-Year Share Buyback Ratio is ranked better than 79.33% of 658
companies
in the Biotechnology industry
Industry Median: -12.15
vs MEX:AGIO: -3.20
Agios Pharmaceuticals (MEX:AGIO) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Agios Pharmaceuticals 10-Year Share Buyback Ratio Related Terms
MEX:AGIO vs GENB, ZYME, ZBIO: 10-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals 10-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's 10-Year Share Buyback Ratio falls into.
Agios Pharmaceuticals 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -3.20 mean?
Agios Pharmaceuticals (MEX:AGIO) has a 10-Year Share Buyback Ratio of -3.20 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #136 out of 658 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Agios Pharmaceuticals' 10-Year Share Buyback Ratio too high?
Agios Pharmaceuticals' current 10-Year Share Buyback Ratio is -3.20. Based on the distribution chart, Agios Pharmaceuticals ranks #136 out of 658 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' 10-Year Share Buyback Ratio compare to GENB and ZYME?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #136 out of 658 companies for 10-Year Share Buyback Ratio. This places Agios Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current 10-Year Share Buyback Ratio is -3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (MEX:AGIO) has a current 10-Year Share Buyback Ratio of -3.20. The stock's GF Value™ is MXN4,502.37, compared to a current price of MXN1,222.00 — trading 72.9% below its estimated fair value. The current 10-Year Share Buyback Ratio is -3.20. Agios Pharmaceuticals' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current 10-Year Share Buyback Ratio is -3.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,222.00 is trading 72.9% below its estimated GF Value™ of MXN4,502.37.
Key valuation signals for MEX:AGIO:
10-Year Share Buyback Ratio: -3.20
GF Value™: MXN4,502.37 vs. price of MXN1,222.00 (72.9% below fair value)
No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on cellular metabolism and rare diseases, particularly classical hematology. Its lead product, Pyrukynd (mitapivat), is an oral pyruvate kinase activator approved for pyruvate kinase deficiency, a rare inherited hemolytic anemia, and the company is also developing it for other hemolytic anemias and thalassemia. Agios markets Pyrukynd in the United States and several other countries and generates revenue primarily from product sales, alongside collaboration and royalty income. Its pipeline includes tebapivat, a pyruvate kinase activator being studied in lower-risk myelodysplastic syndromes and sickle cell disease, and earlier-stage programs in hematology. Agios previously developed oncology therapies, including Tibsovo (ivosidenib), before divesting that business to focus on rare genetic and hematologic diseases.
46GF Score
Get the complete analysis for MEX:AGIO
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AGIO has been successfully added to your 
